Tocilizumab for rheumatoid arthritis with chronic hepatitis B virus infection without antiviral therapy

Journal of Rheumatology

Volumn 37, Issue 5, 2010, Pages 1066-

  Nagashima, Takao ^a   Minota, Seiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; TOCILIZUMAB;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; VIRUS CARRIER; VIRUS LOAD; VIRUS REACTIVATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HEPATITIS B, CHRONIC; HUMANS;

EID: 77951829706     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.091220     Document Type: Letter

References (4)

1. Wendling D, Di Martino V, Herbein G. Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we? [editorial]. J Rheumatol 2009;36:1107-1108.
2. Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology 2008;47:1838-1840.
3. Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airo P. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009;36:1188-1194.
4. European Association for the Study of the Liver. Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242.